Neumora Therapeutics Stock Soars 11.76% on Bullish Analyst Sentiment
On June 9, 2025, NeumoraNMRA-- Therapeutics' stock surged by 11.76% in pre-market trading, reflecting a significant upward momentum in investor sentiment.
Neumora Therapeutics has garnered attention from analysts, with nine experts setting an average twelve-month price target of $9.29. This target suggests a substantial potential upside, indicating strong confidence in the company's future performance.
The company's market capitalization stands at $0.16 billion USD, positioning it as the 8486th most valuable company globally. This valuation underscores the company's growth potential and its standing in the competitive landscape.

Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments
No comments yet